Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Cannot have received: chemotherapy

Had chemotherapy within 5 years prior to study treatment

Cannot have received: investigational drug

Have received any investigational drugs within 28 days prior to study treatment

Cannot have received: anti-PD-1 therapy

Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent

Cannot have received: chemotherapy (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan)

Has received prior therapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, or PARP inhibitor

Cannot have received: PARP inhibitor

Has received prior therapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, or PARP inhibitor

Cannot have received: radiation therapy

Has received radiotherapy for pancreatic cancer